Baseline characteristics | Â |
---|---|
Sex | Â |
 Men | 4,715,243 (51.3%) |
 Women | 4,468,903 (48.7%) |
Age categories | Â |
 12–15 years | 401,186 (4.4%) |
 16–19 years | 387,685 (4.2%) |
 20–29 years | 977,758 (10.7%) |
 30–39 years | 1,130,699 (12.3%) |
 40–49 years | 1,493,328 (16.3%) |
 50–59 years | 1,665,591 (18.1%) |
 60–69 years | 1,254,101 (13.7%) |
 70–79 years | 1,026,382 (11.2%) |
 80 + years | 847,416 (9.2%) |
Cardiac comorbidities | Â |
 Arrhythmic myocardiopathy | 237,941 (2.6%) |
 Arterial vascular disease | 76,321 (0.8%) |
 Familial and non-familial hypercholesterolaemia | 274,477 (3.0%) |
 Heart failure | 161,551 (1.8%) |
 Hypertension | 1,285,967 (14.0%) |
 Ischaemic heart disease | 246,631 (2.7%) |
 Non-arrhythmic myocardiopathy | 245,683 (2.7%) |
 Valvular heart disease | 69,656 (0.8%) |
 Venous vascular disease | 41,184 (0.5%) |
 At least one cardiac comorbidity | 2,255,136 (24.5%) |
Vaccine status | |
---|---|
 First dose | 7,907,765 (86.1%) |
  Oxford-AstraZeneca | 1,223,681 (13.3%) |
  Janssen | 289,989 (3.2%) |
  Moderna | 1,024,935 (11.2%) |
  Pfizer-BioNTech | 5,369,160 (58.5%) |
 Second dose | 7,165,379 (78.0%) |
  Oxford-AstraZeneca | 1,041,884 (11.3%) |
  Moderna | 970,629 (10.6%) |
  Pfizer-BioNTech | 5,152,866 (56.1%) |
 Third dose (booster) | 1,052,469 (11.5%) |
  Moderna | 108,319 (1.2%) |
  Pfizer-BioNTech | 944,150 (10.3%) |